JPH09188658A5 - - Google Patents

Info

Publication number
JPH09188658A5
JPH09188658A5 JP1996340918A JP34091896A JPH09188658A5 JP H09188658 A5 JPH09188658 A5 JP H09188658A5 JP 1996340918 A JP1996340918 A JP 1996340918A JP 34091896 A JP34091896 A JP 34091896A JP H09188658 A5 JPH09188658 A5 JP H09188658A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
composition according
high density
density lipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP1996340918A
Other languages
English (en)
Japanese (ja)
Other versions
JPH09188658A (ja
Filing date
Publication date
Priority claimed from DE19547648A external-priority patent/DE19547648A1/de
Application filed filed Critical
Publication of JPH09188658A publication Critical patent/JPH09188658A/ja
Publication of JPH09188658A5 publication Critical patent/JPH09188658A5/ja
Abandoned legal-status Critical Current

Links

JP8340918A 1995-12-20 1996-12-20 リポタンパク質およびクロトンアミドを含有する組成物 Abandoned JPH09188658A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19547648A DE19547648A1 (de) 1995-12-20 1995-12-20 Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19547648:4 1995-12-20

Publications (2)

Publication Number Publication Date
JPH09188658A JPH09188658A (ja) 1997-07-22
JPH09188658A5 true JPH09188658A5 (enExample) 2004-11-18

Family

ID=7780700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8340918A Abandoned JPH09188658A (ja) 1995-12-20 1996-12-20 リポタンパク質およびクロトンアミドを含有する組成物

Country Status (8)

Country Link
US (1) US5780592A (enExample)
EP (1) EP0780128B1 (enExample)
JP (1) JPH09188658A (enExample)
AT (1) ATE268603T1 (enExample)
DE (2) DE19547648A1 (enExample)
DK (1) DK0780128T3 (enExample)
ES (1) ES2219678T3 (enExample)
PT (1) PT780128E (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251433B1 (en) * 1996-08-13 2001-06-26 Chiron Corporation Polycationic polymers
US6649362B2 (en) 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
ATE473759T1 (de) 1998-05-22 2010-07-15 Univ Leland Stanford Junior Bifunktionelle moleküle sowie darauf basierende therapien.
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
GB9919713D0 (en) * 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
DE10112926B4 (de) * 2001-03-13 2005-11-10 Schebo Biotech Ag Verwendung von Aminooxyacetat zur Tumorbehandlung
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
AR033459A1 (es) * 2001-04-05 2003-12-17 Aventis Pharma Inc Uso de (41-trifluorometilfenil)-amida del acido (z)-2-ciano-3-hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
CA2457840C (en) * 2001-08-20 2011-10-11 Zlb Bioplasma Ag Hdl for the treatment of stroke and other ischemic conditions
EP1285662A1 (en) * 2001-08-20 2003-02-26 ZLB Bioplasma AG Reconstituted HDL for the treatment of stroke and ischemic conditions
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
US20030162758A1 (en) * 2001-12-07 2003-08-28 Schwartz Daniel M. Treatment for age-related macular degeneration (AMD)
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
IL164185A0 (en) * 2002-04-16 2005-12-18 Fujisawa Pharmaceutical Co Pharmaceutical compositions containing trifluoromethylphenyl amide derivatives
BR0317687A (pt) 2002-12-23 2005-11-22 4Sc Ag Compostos aromáticos como agentes antiinflamatórios, imunomoduladores e antiproliferativos
CA2584655A1 (en) * 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
AU2005201035B2 (en) * 2005-03-08 2012-04-26 Csl Behring Ag Treatment of inflammatory conditions of the intestine
US7759315B2 (en) * 2005-03-09 2010-07-20 Csl Behring Ag Treatment of inflammatory conditions of the intestine
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2100881A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Pyrimidyl- or pyridinylaminobenzoic acid derivatives
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
DK3395372T3 (da) 2009-02-20 2022-04-19 Enhanx Biopharm Inc System til afgivelse af glutathion-baseret medikament
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
CN110075069A (zh) 2009-05-06 2019-08-02 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
UA108760C2 (uk) 2010-07-01 2015-06-10 Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
HUE067375T2 (hu) 2018-03-16 2024-10-28 Immunic Ag Új kalciumsó polimorfok gyulladásellenes, immunmodulátor és proliferáció elleni szerekként
US11376232B2 (en) 2020-04-21 2022-07-05 Immunic Ag Vidofludimus for use in the treatment or prevention of viral diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
HU222234B1 (hu) * 1990-05-18 2003-05-28 Aventis Pharma Deutschland Gmbh. Eljárás izoxazol-4-karbonsav-amidok és hidroxi-alkilidén-cián-ecetsav-amidok, a vegyületeket tartalmazó gyógyászati készítmények és az ismert vegyületeket tartalmazó rákellenes hatású gyógyszerkészítmények előállítására
IL99811A (en) * 1990-10-30 1996-03-31 Roussel Uclaf 3-cycloalkyl-propanamides their tautomer forms and their salts preparation process and compositions containing them
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
NZ244814A (en) * 1991-10-23 1994-06-27 Hoechst Ag N-phenyl-2-cyano-3-hydroxycrotonamide derivatives and pharmaceutical compositions
GB9200275D0 (en) 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
TW314467B (enExample) * 1993-03-31 1997-09-01 Hoechst Ag
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease

Similar Documents

Publication Publication Date Title
JPH09188658A5 (enExample)
JP2004531517A5 (enExample)
CN104703976B (zh) 双(氟烷基)‑1,4‑苯并二氮杂*酮化合物作为notch抑制剂
JPWO2022173678A5 (enExample)
JP2010530372A5 (enExample)
RU99115750A (ru) Новые соединения с анальгезирующим действием
JP2002543121A5 (enExample)
JP2005526107A5 (enExample)
RU96118132A (ru) Соединения, активные в новом сайте на рецептор-регулируемых кальциевых каналах и используемые для лечения неврологических расстройств и заболеваний
RU2005103398A (ru) Производные 7,8,9,10-тетрагидро-6h-азепино-, 6,7,8,9-тетрагидропиридо-и 2,3-дигидро-2h-пирроло-[2,1-b]-хиназолинона
JP2004517843A5 (enExample)
JP2010500376A5 (enExample)
JP2005516967A5 (enExample)
RU2008119692A (ru) Новые 1-азабициклоалкилпроизводные для лечения психических растройств
JP2001510843A5 (enExample)
JP2004513940A5 (enExample)
JP2006504738A5 (enExample)
JP2018522838A (ja) ｍＩＤＨ１阻害剤としてのＮ−メンチルベンズイミダゾール
JP2001515872A (ja) 薬剤の経口生物学的利用能を高めるための方法、組成物およびキット
JP2013511526A5 (enExample)
JP2011518168A5 (enExample)
JP2006513222A5 (enExample)
RU2007116987A (ru) Новые соединения
RU2006102129A (ru) Производные пиррол-2, 5-дитиона в качестве модуляторов печеночных х-рецепторов
WO2019149255A1 (zh) 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途